TFAP2α and Chemotherapy Response in Bladder Cancer
Author Information
Author(s): Nordentoft Iver, Dyrskjøt Lars, Bødker Julie S, Wild Peter J, Hartmann Arndt, Bertz Simone, Lehmann Jan, Ørntoft Torben F, Birkenkamp-Demtroder Karin
Primary Institution: Aarhus University Hospital
Hypothesis
High levels of TFAP2α expression predict better chemotherapy response in advanced bladder cancer.
Conclusion
High levels of nuclear and cytoplasmic TFAP2α protein are associated with improved overall survival and progression-free survival in patients with advanced bladder cancer treated with cisplatin-based chemotherapy.
Supporting Evidence
- TFAP2α was identified as a strong independent predictive marker for a good response and survival after cisplatin-containing chemotherapy.
- Strong TFAP2α nuclear and cytoplasmic staining predicted good response to chemotherapy in patients with lymph node metastasis.
- Weak TFAP2α nuclear staining predicted good response in patients without lymph node metastasis.
- In vitro studies showed that TFAP2α knockdown increased proliferation of SW780 cells and reduced sensitivity to cisplatin and gemcitabine.
Takeaway
This study found that a protein called TFAP2α can help doctors know which bladder cancer patients will respond better to chemotherapy.
Methodology
The study used immunohistochemistry on a tissue microarray of 282 bladder cancer tumors and analyzed TFAP2α expression and localization.
Potential Biases
Potential bias in patient selection and retrospective analysis of archived tissues.
Limitations
The study focused only on patients with advanced bladder cancer and may not be generalizable to all bladder cancer patients.
Participant Demographics
Patients with locally advanced or metastatic bladder cancer, including both male and female participants.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website